Senzime AB earnings date
Senzime AB (6YC) Q3 2026 Earnings Report
DE:6YC Q3 2026 EPS Results
- Actual EPS
- -EUR 0.01
- Consensus EPS
- ―
- Beat/Miss
- ―
- One Year Ago EPS
- -EUR 0.01
DE:6YC Q3 2026 Revenue Results
- Actual Revenue
- EUR 2.73M
- Expected Revenue
- EUR 2.74M
- Beat/Miss
- Missed by -EUR 9,166.053
- YoY Revenue Growth
- +13.68%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 10/29/2026
- Time
- Before Open
- Conference Call
- Thursday, October 29, 2026
Senzime AB's next earnings date is estimated for February 18, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly constructive. Senzime reported renewed growth, 43% sensor growth, a record 74% gross margin, lower operating expenses, materially improved EBITDA and cash flow, secured financing, and a reiterated target of positive cash flow within Q4. The main challenges were delayed U.S. deal closures, weaker monitor sales, no Q3 TetraGraph-as-a-Service contracts, ongoing market adoption work, and pending South Korean regulatory approval.
Management reiterated that it is “on path to reach positive cash flow within the fourth quarter,” clarifying that this means “November and December or November or we'll see what it is,” and said this is “the first step”; it is working to drive gross margin “to be in excess of 70%,” expects “70% to 80% of our business” to be recurring revenues, with this “over time” potentially “even higher,” and said “about probably more than 50% of the business over the next 10 years is going to be OEMs”; TetraGraph-as-a-Service has “some Q4 pipeline,” the Philips projects are “progressing as planned” with no market-launch timing disclosed, and South Korea has “a couple of months left” in regulatory submission mode.
- Return to Broad-Based GrowthSenzime reported 14% growth in Q3 and said it grew in all regions. Q3 sales were SEK 30.1 million, with the U.S. remaining the main driver while Asian and European markets were also beginning to take off.
- Strong Sensor and Recurring-Revenue GrowthDisposable sensor sales grew 43% in Q3, with more than 130,000 sensors shipped during the quarter. Trailing twelve-month sensor growth was 53%, and sensors represented 83% of Q3 business. Management said approximately 80% of the business is recurring sensor revenue.
- Expanding Installed Base and Customer ReachSenzime has delivered approximately 6,000 systems to operating rooms, serves about 800 hospitals in approximately 30 markets, and has monitored more than 1.3 million patients. The company said its opportunity extends to more than 400,000 operating rooms.
- Higher Customer UtilizationWeekly average utilization among key U.S. accounts increased 60% during the year. Management attributed the improvement to customer training, analytics, support services, and efforts to standardize use of the technology.
- University of Miami Utilization SuccessUniversity of Miami, a Senzime customer since approximately 2023, reached about 80% utilization after adopting the next-generation TetraGraph in mid-2025 and institutionalizing product-use protocols.
- Pediatric Market MomentumFollowing the publication of European guidelines recommending electromyography-based monitoring for children receiving paralytic drugs, Senzime said the pediatric growth trajectory doubled and that it is attracting pediatric hospitals globally.
- Philips OEM and Commercial PartnershipSenzime announced a landmark Philips OEM and commercial partnership involving co-development and co-commercialization. Management said the projects are progressing as planned and that OEM partnerships are expected to represent more than 50% of the business over the next 10 years.
- U.S. Veterans Affairs Agreement and Hospital WinsSenzime secured a five-year sole-source agreement with the U.S. Veterans Affairs system, which has more than 170 hospitals. The company also won additional hospital contracts, including a major eastern U.S. system where 60 TetraGraph systems were deployed.
- Record Gross MarginGross margin reached 74% in Q3, up from 61% in the prior-year quarter and representing a 13-percentage-point improvement. Management cited redesigned sensors, partly European-based production, improved unit economics, favorable product mix, and pricing and innovation initiatives.
- Lower Operating ExpensesOperating expenses decreased 15% year over year, or approximately SEK 6 million in Q3. Management attributed this to reduced headcount, greater commercial focus, AI-enabled productivity improvements in the technology team, and a lower cost base.
- Improving EBITDA and Progress Toward ProfitabilityQ3 EBITDA improved 59% year over year to negative SEK 8 million from negative SEK 19.4 million. September was described as nearly breakeven, and both the U.S. and German entities reported EBITDA-positive results before allocated head-office expenses.
- Significantly Improved Cash FlowQuarterly cash flow improved 70%, with the cash burn declining to negative SEK 8.7 million from negative SEK 28.3 million in the prior-year quarter. Management attributed the improvement to higher sales, better gross margin, lower expenses, and faster inventory movement and customer payments.
- Funding Secured Through ProfitabilitySenzime refinanced its loan package and has access to a SEK 35 million credit line. With SEK 28.7 million in cash at quarter-end, total available funding was SEK 63.7 million. Management said this provides the capital needed to reach profitability.
- Positive Cash Flow Target ReiteratedManagement reiterated its expectation of reaching positive cash flow within Q4, clarifying that the target refers to November and December, or November, depending on the outcome.
- Software and Predictive Recovery InnovationManagement said software updates are well received and described the predictive recovery algorithm as an industry-first feature designed to predict the onset of recovery and help individualize the final phase of waking from surgery.
- International Market ProgressSenzime is approved in Brazil and Mexico and said Latin America is progressing well, with major initiatives planned in Brazil in November. Japan has developed well following the spring rollout of the next-generation system, with trials, monitor deployments, and utilization increasing.
- Improved Product Economics and Recurring Mix OutlookManagement expects recurring revenues to remain approximately 70% to 80% of the business and potentially become an even larger share over time. It also said unit economics are improving for both sensors and monitors and that long-term gross margin could be higher than current levels.
DE:6YC Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 18, 2027 | 2026 (Q4) | ―- | -0.02 | ― | ― |
| Oct 29, 2026 | 2026 (Q3) | ―-0.01 | -0.01 | 55.56% (+0.01) | |
| Jul 16, 2026 | 2026 (Q2) | ―-0.01 | -0.02 | 44.26% (+0.01) | |
| Apr 22, 2026 | 2026 (Q1) | ―-0.01 | -0.02 | 45.00% (+0.01) | |
| Feb 18, 2026 | 2025 (Q4) | ―-0.02 | -0.02 | -36.50% (-0.01) | |
| Oct 29, 2025 | 2025 (Q3) | -0.01-0.01 | -0.02 | 37.69% (+0.01) | |
| Jul 18, 2025 | 2025 (Q2) | -0.02-0.02 | -0.03 | 12.86% (+0.00) | |
| Apr 22, 2025 | 2025 (Q1) | -0.02-0.02 | -0.02 | -30.00% (-0.01) | |
| Feb 17, 2025 | 2024 (Q4) | -0.02-0.02 | -0.03 | 33.33% (+0.01) | |
| Nov 06, 2024 | 2024 (Q3) | -0.02-0.02 | -0.03 | 13.33% (+0.00) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


